This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
West Nile vaccine (CRXL)
Johnson & Johnson
Drug Names(s): PER.C6-based West Nile virus vaccine
Description: The West Nile virus vaccine (CRXL) is an inactivated whole virus. The West Nile virus is grown on PER.C6 cells and then inactivated for application in the vaccine.
Deal Structure: In October 2010, Johnson & Johnson and Crucell announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately Euro 1.75 billion in a recommended cash tender offer. The acquisition was declared unconditional and completed in February 2011.
West Nile vaccine (CRXL) News
Pink Sheet FDA Performance Tracker: CBER Approvals
Additional information available to subscribers only: